Menu Back to 1st-DIA-Risk-Management-Workshop-in-Japan

Program Committee

  • Rei  Maeda
    Rei Maeda Senior Regulatory Scientist, Surveillance & Epidemiology, Global Patient Safety
    Eli Lilly Japan K.K., Japan
  • Kasumi  Daidoji, MSc, RPh
    Kasumi Daidoji, MSc, RPh Associate Director, Drug Fostering & Evolution Coordination Dept, CMA HQs
    Eisai Co., Ltd., Japan
  • Akiko  Hori, MD, PhD
    Akiko Hori, MD, PhD Review Director, Office of Safety II
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Rie  Matsui, RPh
    Rie Matsui, RPh Director, Regional Labeling Head for Asia, International Labeling Group
    Pfizer Japan Inc., Japan
  • Koh  Miyakawa
    Koh Miyakawa Director
    Takeda Pharmaceutical Company Limited, Japan
  • Shinichi  Nishiuma, MD
    Shinichi Nishiuma, MD Senior Medical Advisor, Global Patient Safety
    Eli Lilly Japan K.K., Japan
  • Mitsuo  Saito, PhD
    Mitsuo Saito, PhD Associate Professor
    Teikyo Heisei University, Japan
  • Junko  Sato, DrSc, PhD
    Junko Sato, DrSc, PhD International Coodination Officer
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Load More